Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)


Phase 1 study consisting of two parts. Part 1 is a weight-based dose escalation following a 3+3 design of dose-escalating cohorts. Part 2 includes administration at fixed doses. After enrollment, subjects may receive a lymphodepletion therapy regimen before administration of allogeneic CAR-T cells, administered as a single or multiple doses. Treated subjects will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.


Poseida Therapeutics

Status of enrollment

Accepting patients

Ages Eligible for Study

For adults ages 18 years and up

Genders Eligible for Study

Females and males

Disease indication

Multiple Myeloma

Principal Investigator

Sandy Wong, MD


Justin Zheng

[email protected]

Additional study eligibility details can be found at UCSF Clinical Trials.